The preclinical candidates are designed to target hematological and solid tumors. The company's Allo-evasion technology enables the candidates to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients.

Century anticipates beginning clinical testing of its first off-the-shelf cell therapy products in 2022, as well as the generation of multiple investigational new drug (IND) applications annually in the next years.

The financing was led by Casdin Capital.

Artiva nabs $120M for NK cell therapies
Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research...

Luminary licenses TcBuster CAR T tech from Bio-Techne
Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the...

Oncolytics reports results of immuno-oncolytic virus with CAR T therapy
Oncolytics Biotech is reporting new data from a preclinical study where pelareorep, its proprietary immuno-oncolytic virus and chimeric antigen receptor...

Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...

Notch nabs $85M in funding for stem cell-based cell therapies
Notch Therapeutics has closed $85 million in series A financing to continue the development of its portfolio of induced pluripotent stem cell-derived...